U

u/Virtual_Secretary_98

5.0 ★★★★★ Posted today
Reddit r/ValueInvesting
· tracked since May 2026
Ideas 4
Long / short 4 L/0 S
Win rate -
Tracked posts 1 1.00/day
Avg return -
Long return -
Short return -
New ideas 4 last 30d
Most mentioned
Best trades
Loading live returns
Worst trades
Loading live returns

Pick return distribution

Live distribution of all picks with entry price. Right tail = home runs.
< -30%-30/-10-10/00/+20+20/+50+50/+100> +100%
Bottom 10%
-
Median
-
Top 10%
-

Average returns

first-opened thesis horizon: return + win-rate
7 days 0 eval.
-
L - S -
Win rate -
30 days 0 eval.
-
L - S -
Win rate -
90 days 0 eval.
-
L - S -
Win rate -
Closed-window returns from the first opened position per ticker/side. 90d = picks opened 90+ days ago
Result
Theme Stance
Ticker
Side
Theme
Entry
P&L
Thesis
First opened
Mentions
Source
Long
Consumer
$156.30
-
Reddit reported strong earnings with fast revenue growth and true profitability. If the market weren't distracted by semiconductors/memory, Reddit’s momentum would likely drive a parabolic move. Reddit is undervalued relative to its growth trajectory and now cash-flow positive, making it a compelling long. Ad revenue slowdown, increased competition, or a broader tech sell-off could derail momentum.
May 08
Long
AI/Semi
$414.92
-
Microsoft is a stable mega-cap with Azure, AI, and recurring revenue; commenters note it is overlooked for quicker gains elsewhere. Impatient traders miss MSFT’s steady compounding, making it a safe long in a frothy market. Microsoft remains undervalued relative to its cash flow and AI lead – a core hold. Regulatory headwinds, AI competition, or a broader tech correction.
May 08
Long
AI/Semi
$609.35
-
Meta is cited alongside MSFT and PFE as a name with remaining upside. Meta’s advertising recovery, cost discipline, and AI investments support margin expansion. Still cheap on forward earnings relative to growth potential. Regulation, Apple privacy changes, or ad spending slowdown.
May 08
Long
Healthcare
$25.68
-
Pfizer is mentioned as a pharma pick amid rotation away from tech. Pharma offers defensive value, and PFE has a pipeline and dividend after post-COVID pullback. Potential value play if the sector rotates out of memory/chips. Patent cliffs, weak pipeline execution, or continued market preference for growth.
May 08
Showing 4 of 4 picks · sorted by mentions